Curatussin

Description

CuraTUSSIN is presented in a label format, effective from January 1, 2024. The media type for this label is an image in JPEG format, identified as CuraTUSSIN Label.jpg.

Uses and Indications

This drug is indicated for the facilitation of mucus clearance in patients with respiratory conditions. It helps to loosen phlegm and thin bronchial secretions, thereby making coughs more productive.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The recommended dosage for the medication varies by age group and should not exceed 6 doses within a 24-hour period.

For adults and children aged 12 years and older, the dosage is 2 to 4 teaspoonfuls administered every 4 hours.

For children aged 6 years to under 12 years, the dosage is 1 to 2 teaspoonfuls every 4 hours.

For children aged 2 years to under 6 years, the dosage is 1/2 to 1 teaspoonful every 4 hours.

For children under 2 years of age, it is advised to consult a physician before administration.

Healthcare professionals should ensure that patients adhere to the specified dosing intervals and do not exceed the maximum daily limit.

Contraindications

Use is contraindicated in the following situations:

• The product should be kept out of reach of children to prevent accidental ingestion.

• In the event of an overdose, immediate medical assistance should be sought or contact with a Poison Control Center is advised.

Warnings and Precautions

Patients should be advised to consult a healthcare professional prior to use if they experience a cough accompanied by excessive phlegm (mucus) or if the cough is chronic, particularly in cases related to smoking, asthma, chronic bronchitis, or emphysema.

In the event that a cough persists for more than 7 days, recurs, or is accompanied by additional symptoms such as fever, rash, or a persistent headache, it is imperative to discontinue use and seek medical advice. These symptoms may indicate a serious underlying condition that requires further evaluation.

For individuals who are pregnant or breastfeeding, it is essential to consult a healthcare provider before initiating use of this product to ensure safety for both the mother and child.

This product should be stored out of reach of children. In the case of an overdose, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended without delay.

Side Effects

Patients should be aware of several important warnings associated with the use of this medication. It is advised to consult a doctor prior to use if the patient has a cough that occurs with excessive phlegm (mucus) or if the cough is chronic, such as that which may occur with smoking, asthma, chronic bronchitis, or emphysema.

Patients are also instructed to discontinue use and seek medical advice if the cough persists for more than 7 days, recurs, or is accompanied by symptoms such as fever, rash, or a persistent headache, as these may indicate a serious underlying condition.

For those who are pregnant or breastfeeding, it is essential to consult a healthcare professional before using this medication. Additionally, the product should be kept out of reach of children, and in the event of an overdose, immediate medical assistance should be sought or contact with a Poison Control Center should be made.

Drug Interactions

There are no specific drug interactions or laboratory test interactions identified in the available data. Therefore, no dosage adjustments or monitoring recommendations are necessary at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Curatussin (guaifenesin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients aged 6 years to under 12 years may be administered 1-2 teaspoonfuls every 4 hours. For children aged 2 to under 6 years, the recommended dosage is 1/2 to 1 teaspoonful every 4 hours. For infants and children under 2 years, it is advised to consult a doctor before administration.

Geriatric Use

There is no specific information available regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. It is advisable to monitor these patients closely for any adverse effects or changes in efficacy.

Pregnancy

Pregnant patients and those who are breastfeeding should consult a healthcare professional prior to using this medication. The potential risks and benefits must be carefully considered in these populations to ensure the safety of both the mother and the fetus or infant.

Lactation

Lactating mothers are advised to consult a health professional prior to using this medication. There is currently no available data on the excretion of this drug in human breast milk or its effects on breastfed infants. Therefore, caution is recommended when administering this medication to lactating individuals.

Renal Impairment

There is no specific information regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

In the event of an overdose, it is imperative to seek immediate medical assistance or contact a Poison Control Center without delay. Prompt intervention is crucial to mitigate potential adverse effects associated with the overdose.

Healthcare professionals should be aware that the symptoms of overdose may vary depending on the substance involved. Therefore, a thorough assessment of the patient's condition is essential to determine the appropriate course of action.

Management of an overdose typically involves supportive care and symptomatic treatment. Continuous monitoring of the patient's vital signs and clinical status is recommended. In cases where specific antidotes are available, their administration should be considered based on the clinical scenario and the substance involved.

It is essential for healthcare providers to remain vigilant and act swiftly in the management of overdose situations to ensure optimal patient outcomes.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep this medication out of reach of children to prevent accidental ingestion. In the event of an overdose, patients should be instructed to seek medical help immediately or contact a Poison Control Center for assistance. It is essential for patients to understand the importance of these precautions to ensure their safety and the safety of others.

Storage and Handling

The product is supplied in a container that must be stored at room temperature. It is essential to protect the product from light exposure to maintain its integrity. The bottle should be kept tightly closed when not in use to prevent contamination and degradation. Additionally, the product should be discarded after opening to ensure safety and efficacy.

Additional Clinical Information

Patients should be informed that the medication is administered orally. Clinicians are advised to counsel patients to consult a doctor prior to use if they experience a cough accompanied by excessive phlegm, or if the cough is chronic, such as that associated with smoking, asthma, chronic bronchitis, or emphysema.

Patients should discontinue use and seek medical advice if the cough persists for more than 7 days, recurs, or is accompanied by fever, rash, or a persistent headache, as these may indicate a serious condition. Pregnant or breastfeeding patients should also consult a healthcare professional before use. Additionally, the medication should be kept out of reach of children, and in the event of an overdose, medical assistance or contact with a Poison Control Center is essential.

Drug Information (PDF)

This file contains official product information for Curatussin, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)